Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136322 | 0.82 | KCNH2 (0.45) | GRM5FFAR1CYP3A4 | |
| SCHEMBL3901448 | 0.80 | APP (0.42) | CYP1A2CYP3A4CHRNB2CHRNA4 | |
| SCHEMBL30469478 | 0.73 | GRM5 (0.69) | GRM5FFAR1FFAR4HTTSMN1; SMN2 | |
| SCHEMBL4562089 | 0.73 | GRM5 (0.69) | GRM5FFAR1FFAR4HTTSMN1; SMN2 | |
| SCHEMBL30469481 | 0.73 | GRM5 (0.69) | GRM5FFAR1FFAR4HTTSMN1; SMN2 | |
| SCHEMBL8217128 | 0.72 | GRM5 (0.49) | GRM5FFAR1FFAR4ACHE | |
| SCHEMBL8993127 | 0.71 | GRM5 (0.52) | GRM5FFAR1CYP1A2CYP3A4FFAR4 | |
| SCHEMBL28472086 | 0.70 | GRM5 (0.47) | GRM5FFAR1FFAR4ACHE | |
| SCHEMBL5578049 | 0.70 | CYP1A2 (0.35) | GRM5FFAR1CYP1A2 | |
| SCHEMBL6787301 | 0.70 | PTGS2 (0.43) | CYP3A4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580962-B2 | Spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD. (IT) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GPR65, GRIK5 | GRM5 1/4885FFAR1 425/4885CYP1A2 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.